ARCH Venture Partners X, LLC

SEC Form 4 insider trading activity

ARCH Venture Partners X, LLC has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2025. 1 of those filings fall inside the rolling window. Most recent filing: Oct 29, 2025.

On the most recent filing, ARCH Venture Partners X, LLC is listed as 10% Owner at Neumora Therapeutics, Inc. Inside the rolling window, ARCH Venture Partners X, LLC reported 1 open-market purchase totaling $5.0M in NMRA and no open-market sales.

Companies traded

Other insiders at NMRA

Insider Buying

$5.0M

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Companies

1

in the rolling window

Source
NMRA
ARCH Venture Partners X, LLC
Purchase$5.0MOct 29SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has ARCH Venture Partners X, LLC made?

ARCH Venture Partners X, LLC has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2025.

Which companies does ARCH Venture Partners X, LLC trade?

ARCH Venture Partners X, LLC has filed SEC Form 4 disclosures for 1 company, including NMRA.

When was ARCH Venture Partners X, LLC's most recent SEC Form 4 filing?

ARCH Venture Partners X, LLC's most recent SEC Form 4 filing on Tracefour is dated Oct 29, 2025.

What is ARCH Venture Partners X, LLC's total buy and sell value in the current window?

Inside the rolling retention window, ARCH Venture Partners X, LLC bought $5.0M and sold $0 based on SEC Form 4 filings.

What was ARCH Venture Partners X, LLC's largest disclosed transaction?

The largest disclosed transaction in the current window is a purchase of 1,915,700 NMRA shares on 2025-10-27, worth $5.0M, per SEC Form 4 filings.